One thing we could say about the analysts on Esperion Therapeutics, Inc. (NASDAQ:ESPR) – they aren’t optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.
After this downgrade, Esperion Therapeutics’ ten analysts are now forecasting revenues of US$189m in 2020. This would be a huge 27% improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing US$220m of revenue in 2020. The consensus view seems to have become more pessimistic on Esperion Therapeutics, noting the measurable cut to revenue estimates in this update.
View our latest analysis for Esperion Therapeutics
NasdaqGM:ESPR Past and Future Earnings April 5th 2020
The Bottom Line
The clear low-light was that analysts slashing their revenue forecasts for Esperion Therapeutics this year. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn’t be surprised if the market became a lot more cautious on Esperion Therapeutics after today.
But wait – there’s more! At least one of Esperion Therapeutics’ ten analysts has provided estimates out to 2024, which can be seen for free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
If you spot an error that warrants correction, please contact the editor at [email protected]. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
